FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
X

Find Clinical Drug Pipeline Developments & Deals by Daiichi Sankyo Co Ltd

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DS-1062

            Therapeutic Area: Oncology Product Name: DS-1062

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: Gustave Roussy

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 22, 2020

            Details:

            The collaboration focuses on clinical and translational research, including potential combination strategies for DS-1062, in patients with advanced non-small cell lung cancer, and for patritumab deruxtecan, in patients with metastatic breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Prasugrel Hydrochloride

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Effient

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 21, 2020

            Details:

            The study was carried out in a double-blind comparative manner to examine the efficacy and safety of prasugrel and clopidogrel in 234 thrombotic stroke patients with one or more risk factors for the recurrence of ischemic stroke.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antimicrobial Resistance Antibiotics

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Funding July 10, 2020

            Details:

            The AMR Action Fund, established to promote the development of new antimicrobial agents for AMR, provides technical assistance and invests about 1 billion US dollars for small biotechnology companies to bring 2 to 4 new antibiotics to patients by 2030.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab Deruxtecan

            Therapeutic Area: Oncology Product Name: DS-8201

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 06, 2020

            Details:

            The MAA is based on the positive results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan monotherapy in patients with HER2 positive metastatic breast cancer who had received two or more prior anti-HER2 regimens.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DS-1062

            Therapeutic Area: Oncology Product Name: DS-1062

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 01, 2020

            Details:

            Phase 1 study now evaluating DS-1062, a TROP2 directed DXd ADC, in patients with advanced/ unresectable or metastatic triple negative breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pexidartinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 26, 2020

            Details:

            CHMP of the European Medicines Agency has adopted a negative opinion on the Marketing Authorization Application For pexidartinib for the treatment of a subset of adult patients with severe tenosynovial giant cell tumor (TGCT).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 12, 2020

            Details:

            Daiichi Sankyo is set to develop a mRNA vaccine candidate to protect against Covid-19 infection in the country. The project, Fundamental Research on the Control of a Novel Coronavirus (2019-nCoV), is supported by the Japan Agency for Medical Research and Development (AMED).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nafamostat

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: The University of Tokyo

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 08, 2020

            Details:

            Through the partnership, The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo have reached a basic agreement on collaborative R&D on a Nafamostat inhalation formulation for the treatment of novel corona virus infection (COVID-19).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DS-1062,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 29, 2020

            Details:

            Strategic research collaboration aims at to evaluating the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate, and KEYTRUDA in patients with previously-treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab Deruxtecan

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Recipient: Syneos Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 28, 2020

            Details:

            Under the agreement, Syneos Health will provide both strategic and operational solutions for three lead Daiichi Sankyo DXd antibody drug conjugates (ADC): DS-1062, U3-1402 and DS-8201 (known as ENHERTU®).

            PharmaCompass